<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C36EE55B-5F90-4CC8-8133-9C6576DB6A0D"><gtr:id>C36EE55B-5F90-4CC8-8133-9C6576DB6A0D</gtr:id><gtr:name>Senexis Ltd Cambridge</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E89C3602-0FB4-4044-A918-58966B8A10B2"><gtr:id>E89C3602-0FB4-4044-A918-58966B8A10B2</gtr:id><gtr:name>University of Reading</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Whiteknights House</gtr:line1><gtr:line2>PO Box 217</gtr:line2><gtr:line4>Reading</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>RG6 6AH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E89C3602-0FB4-4044-A918-58966B8A10B2"><gtr:id>E89C3602-0FB4-4044-A918-58966B8A10B2</gtr:id><gtr:name>University of Reading</gtr:name><gtr:address><gtr:line1>Whiteknights House</gtr:line1><gtr:line2>PO Box 217</gtr:line2><gtr:line4>Reading</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>RG6 6AH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C36EE55B-5F90-4CC8-8133-9C6576DB6A0D"><gtr:id>C36EE55B-5F90-4CC8-8133-9C6576DB6A0D</gtr:id><gtr:name>Senexis Ltd Cambridge</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7A49EEBD-2DF6-4F12-B702-29822695857C"><gtr:id>7A49EEBD-2DF6-4F12-B702-29822695857C</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Hamley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FG030952%2F1"><gtr:id>A20771E8-AF57-47B4-926E-1C30FD3B5861</gtr:id><gtr:title>Amyloid Peptide Conjugates: Visit to Argentina to Develop Collaboration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/G030952/1</gtr:grantReference><gtr:abstractText>We propose to initiate a collaborative programme to examine the effect of peptide/polymer conjugates on amyloid fibrillisation in vitro and in vivo. The conjugates are expected to bind to amyloid and to disrupt fibrillisation. Members of the Reading team will visit Instituto Leloir (Buenos Aires, Argentina) to perform cell viability/cytotoxicity experiments. The Instituto Leloir was founded by the Nobel laureate Luis Federico Leloir and is one of the premier institutions devoted to biochemistry in South America, indeed it has a leading international profile. Members of the Leloir team will visit Reading for x-ray, neutron and electron microscopy experiments. Diseases such as Alzheimer's and type II diabetes are of increasing importance to the aging population in the developed world. They result result from the formation of amyloid in which proteins and peptides form fibrils based on a beta-sheet structure in which the peptide backbone is orthogonal to the fibril axis (cross beta structure). We propose to initiate a collaborative programme to examine the effect of peptide/polymer conjugates on amyloid fibrillisation in vitro and in vivo. The conjugates are expected to bind to amyloid and to disrupt fibrillisation in a stimuli-responsive fashion. The human amyloid peptide, Abeta is implicated in Alzheimers.</gtr:abstractText><gtr:fund><gtr:end>2010-01-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2009-01-29</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>15280</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Senexis Ltd Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Senexis Ltd Cambridge</gtr:description><gtr:id>14B701A1-AB7D-4102-9FB6-EDBD3999FBD9</gtr:id><gtr:outcomeId>b9cf58fab9cf590e-1</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Two publications resulting from this collaborative travel grant</gtr:description><gtr:firstYearOfImpact>2009</gtr:firstYearOfImpact><gtr:id>BCEF5E4C-9B47-408F-80EF-D5C240EEC62B</gtr:id><gtr:impactTypes><gtr:impactType>Societal</gtr:impactType></gtr:impactTypes><gtr:outcomeId>5447a60b286e86.52105246</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>This grant funded travel to Argentina as part of a collaboration which led to publications concerning amyloid, relevant to insulin activity and diabetes</gtr:description><gtr:exploitationPathways>May be relevant to medicial practitioners</gtr:exploitationPathways><gtr:id>8F48EEBB-8BD9-453F-8F6E-F1D0FB62B1DA</gtr:id><gtr:outcomeId>5447a5318dffe4.31031480</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6E543D47-BA08-4322-A6C5-37CAD6F8C30B</gtr:id><gtr:title>A beta-amino acid modified heptapeptide containing a designed recognition element disrupts oligomerization and fibrillization of the amyloid beta pept</gtr:title><gtr:parentPublicationTitle>ChemBioChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b2a2e76b3a513b1aa1a3b71271ccfff"><gtr:id>5b2a2e76b3a513b1aa1a3b71271ccfff</gtr:id><gtr:otherNames>n/a Castelletto</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>m_8863417393137af4f0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7783ECD3-54B2-4653-9187-810EE681D56E</gtr:id><gtr:title>Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic a? peptide aggregates.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19230c63f4a871ba1904b590200d74f8"><gtr:id>19230c63f4a871ba1904b590200d74f8</gtr:id><gtr:otherNames>de Tullio MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>543531810bc8e9.60081522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AF70AA8-538E-478A-B795-FAA39FEDA2A3</gtr:id><gtr:title>Conductance of amyloid ? based peptide filaments: structure-function relations</gtr:title><gtr:parentPublicationTitle>Soft Matter</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a80a3ba07406d8a09d4d04615771bf5e"><gtr:id>a80a3ba07406d8a09d4d04615771bf5e</gtr:id><gtr:otherNames>Amit M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_55f95d95d2a7af30</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22CA57A4-DC93-4DCC-91E0-CCDAD7965040</gtr:id><gtr:title>A beta-amino acid modified heptapeptide containing a designed recognition element disrupts fibrillization of the amyloid beta-peptide.</gtr:title><gtr:parentPublicationTitle>Journal of peptide science : an official publication of the European Peptide Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb145344eaa7cf0c2033992c0c10ec6c"><gtr:id>eb145344eaa7cf0c2033992c0c10ec6c</gtr:id><gtr:otherNames>Castelletto V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1075-2617</gtr:issn><gtr:outcomeId>doi_55f952952668b248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31CCDC63-78E0-45B0-8663-58D59DC1C667</gtr:id><gtr:title>Control of strand registry by attachment of PEG chains to amyloid peptides influences nanostructure</gtr:title><gtr:parentPublicationTitle>Soft Matter</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb145344eaa7cf0c2033992c0c10ec6c"><gtr:id>eb145344eaa7cf0c2033992c0c10ec6c</gtr:id><gtr:otherNames>Castelletto V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_55f95d95d29d8961</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/G030952/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>60</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>E847DD9B-2053-4BC7-97A9-4213B185C968</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Materials sciences</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>0B9701E7-D17F-4963-82DA-B3926A65B50A</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Biological &amp; Medicinal Chem.</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>454398F2-57A6-4959-8845-0F248CF4D5C4</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Chemical Synthetic Methodology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>063026C5-CD0B-48AB-82F3-6359499A95D4</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Materials Synthesis &amp; Growth</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>